Position in TLRY
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$516,202
-$210,866 QoQ
Shares Held
79,784
-0.9% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in TLRY Over Time
Shares Held
Position Value (USD)
Derivatives in TLRY
reported options exposure · as of Dec 31, 2025CallValue
$31,605
CallShares
3,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Cetera Investment Advisers holds $48,125,230 across 32 Drug Manufacturers - Specialty & Generic names. TLRY ranks #18 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
80,566 | $9,523,706 | |
| 2 | VTRS |
Viatris Inc
|
385,999 | $5,214,846 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
8,648 | $5,128,091 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
224,015 | $4,148,757 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
121,502 | $2,907,542 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
20,245 | $2,667,076 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
87,216 | $2,626,945 | |
| 8 | HLN |
Haleon plc
|
247,741 | $2,479,887 |
All Filings in TLRY
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $516,202 | 79,784 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $31,605 | 3,500 | Call | Sole | 2026-02-17 | |
| 2025-12-31 | $727,068 | 80,517 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||